100 patient multi-center study of the Episealer® knee implant fully recruited

Episurf Medical (NASDAQ: EPIS B) today announces that a European large multi-center study with 100 Episealer patients has been fully recruited. The patients are followed-up at 3, 6, 12, 24 and 60 months post-operatively with clinical scores focusing on pain relief and knee function. The patients have been enrolled since 2014 and the last surgery was recently performed.

The surgeons involved in the clinical study are eleven leading European orthopaedic surgeons. Dr. Med. Johannes Holz from Orthocentrum Hamburg, Germany, has been appointed principal investigator for the study. The study is expected to yield publications on both interim results and final results.  

All three Episealer knee implants, that is Episealer Condyle Solo, Episealer Trochlea Solo and Episealer Femoral Twin, are included and evaluated in this study. The clinics involved, mostly university-based, are situated in Germany, the UK, Sweden, Norway, Denmark, Belgium and the Netherlands.

"I am proud and grateful for having been appointed the principal investigator for this study. I am a convinced long-time user of the Episealer device, which works very well in my hands, and I am looking forward to promoting more extensive use by reports from this large, high-quality study.” says Dr. Holz.   

“At Episurf we are extremely glad that this large and highly relevant study with a long-term follow-up is under way.  We know that the patients operated with an Episealer fare well. This will now be shown in peer-reviewed publications in medical journals. In the final analysis, this is what drives market penetration in an evidence-based medical field. I would also like to take the opportunity to thank everyone involved.” comments Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 6 September 2017.